Tools
Author: Feroze Kaliyadan Author: Todd Troxell Editor: Karalikkattil T. Ashique
Updated: 8/8/2023 1:17:32 AM
Introduction
Nevus comedonicus (NC), first described by Kofmann in 1895, is a rare condition considered to be a type of epidermal nevus.Nevus comedonicus presents as grouped, dilated follicular openings with dark keratin plugs. Kofmann initially had suggested labeling the condition 'comedo nevus.'[1]
Etiology
Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Already have an account? Log in
Etiology
The exact etiology has not been clarified. Nevus comedonicus is considered to be an epidermal nevus developing from the hair follicle. The other opinion is that it is a hamartoma derived from the mesodermal part of the pilosebaceous unit. Genetic mosaicism has been proposed to be part of etiology of nevus comedonicus.[2][3]
Epidemiology
The prevalence has been reported to be between 1 in 45,000 to 1 in 100,000. There is no specific gender predilection; males and females can be equally affected. No increased incidence within a specific ethnicity has been reported. Most of the casesdevelop before the age of ten years.[4][5][6]
Pathophysiology
A mutation of Fibroblast Growth Factor Receptor 2 (FGFR2) along with increased expression of interleukin-1-alpha is considered an important factor in the pathogenesis. Other possible factors include gamma-secretase and filaggrin. Recent studies have highlighted the importance of somatic mutations in NEK 9 in nevus comedonicus. NEK9 has been postulated to be important in the regulation of follicular homeostasis. The NEK 9 mutations are associated with increased phosphorylation at Thr210, indicating activation of NEK9 associated kinase. The formation of the comedones in nevus comedonicus also has been associated with other changes such as loss of markers of follicular differentiation and ectopic expression of keratin 10. A recent study has suggested a role for upregulation of ABCA 12 in nevus comedonicus.[2][1][3]
Histopathology
skin biopsy shows the typical features of comedones -dilated follicular ostia filled with keratin.[4][1]
History and Physical
NC develops shortly after birth in about half of patients, and most patients develop the lesions before the age of ten years. The most common affected sites are the face, neck, upper arms, chest, and abdomen. Sites such as the scalp are affected quiterarely. Other rare but reported sites of involvement include the palms and the glans penis. The usual presentation is in the form of a single group of dilated and plugged follicular ostia in a honeycomb pattern. Other patterns seen include linear, segmental, or Blaschkoid. The lesions may rarely be bilateral. Two specific subtypes have been described: (1) a non-pyogenic type and (2) a type associated with the formation of cysts, pustules, and abscesses. Nevus comedonicus can occur in isolation or in combination with systemic abnormalities in the central nervous system, skeletal system, another skin manifestation, or ocular and dental abnormalities. Combination subtypes are known as nevus comedonicus syndrome.[1][7][4][8][9][10]
Evaluation
The diagnosis is usually clinical. Detailed evaluation of the central nervous system, skeletal system, and the eyesisrequired in suspected cases of NC syndrome. A skin biopsy shows the typical dilated follicular ostia filled with keratin. Immunohistochemistry studies have shown an increased expression of proliferating cell nuclear antigen, intercellular adhesion molecule-1 (ICAM-1), HLA-DR, and CD68. Electron microscopy has shown an increased number of Langerhans cells. Usually the clinical diagnosis is quiteobvious with the history of early age of onset and the typical morphology, but in case of atypical presentations other conditions to consider as differentials include atypical acne (e.g., segmental acne and other mosaic acneiform conditions), other acneiform conditions such as chloracne, Favre- Racouchot syndrome (i.e., nodular elastosis with cysts and comedones), and familial dyskeratotic comedones. This last is a relatively rare, autosomal dominantly inherited condition characterized by hyperkeratotic, comedonal lesions. Histological examination shows comedones with associated dyskeratosis.[11]
Recently, dermoscopy has been reported to be useful in the diagnosis of nevus comedonicus. Dermoscopy highlights the typical comedonal lesions. The typical dermoscopy findings described include multiple light and dark brown, circular or barrel shaped hom*ogenous areas with prominent keratin plugs.[12][13]
Treatment / Management
Spontaneous resolution of nevus comedonicus has not been described; however, aggressive treatment is not recommended as nevus comedonicus is essentially a benign condition. Treatment is mainly reserved for cosmetic reasons or when there are complications such as the formation of cysts or abscesses. Cosmetic treatment for the post-inflammatory scarring also might be required. Treatment options include topical and systemic retinoids. These sometimes are combined with topical steroids for their anti-inflammatory action, salicylic acid, or 12% ammonium lactate. Surgical excision and ablative lasers have been tried in NC. Newer treatment avenues being explored include FGFR inhibitors, interleukin-1-alpha inhibitors, and anti-gamma-secretase drugs. Successful treatment of the keratin plugs with a pore strip has been described. Lasers have been described to be effective in the treatment of nevus comedonicus. Ultrapulse carbondioxide lasers and erbium-YAG lasers have been reported to effectively treat lesions of nevus comedonicus. A recent report has mentioned the use of a 1450 nm diode laser in treating nevus comedonicus. It is postulated that sublesional collagen stimulation by the laser might lead to a reduction of the epidermal invagin*tions leading to an improvement in the skin texture.[14][15][16][1][17][18](B3)
Differential Diagnosis
- Acne neonatorum
- Acne vulgaris
- Angiokeratomas
- Chloracne and acne conglobata with extensive comedones
- Epidermal nevus
- Epidermoid cyst
- Familial dyskeratotic comedones
- Favre-Racouchot syndrome
- Infantile acne
- Keratosis pilaris
- Lichen striatus
- Nevus sebaceus
- Tuberous sclerosis
Pearls and Other Issues
Several associations have been reported along with nevus comedonicus and as part of the nevus comedonicus syndrome. Nevus comedonicus syndrome refers to nevus comedonicus presenting with extra cutaneous manifestations usually involving the central nervous system, skeletal system, teeth, and eyes. Common central nervous system abnormalities reported include- seizure disorders, delayed mental development, electroencephalogram abnormalities, microcephaly and transverse myelitis. Skeletal abnormalities include syndactyly, supernumerary digits, scoliosis, and spina bifida. The most common ocular manifestation described is a cataract. Oligodontia is the most reported dental abnormality. Nevuscomedonicussyndrome is considered to be a part of the epidermal nevus syndrome which covers extra cutaneous manifestations occurring in association with conditions like nevus comedonicus, verrucous epidermal nevus, and nevus sebaceus. The other syndromes considered to be part of the group of epidermal nevus syndromes include Schimmelpenning syndrome, phacomatosis pigmentokeratotica, angora hair nevus syndrome, and Becker nevus syndrome.[19][1][20][21][22]
Hidradenitis suppurative can occur along with nevus comedonicus. Hidradenitis suppurative-like lesions complicating nevus comedonicus have been described and mechanical stress has been postulated as a trigger for their development. Other rare systemic associations reported with nevus comedonicus include Alagille syndrome, spinal dysraphism, hypothyroidism, and Paget bone disease. Primary dermatological conditions occurring in association with nevus comedonicus include basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, linear morphea, lichen striatus, accessory breast tissue, epidermolytic hyperkeratosis, nevoid hyperkeratosis of areola, hidradenoma papilliform, syringocystadenoma papilliform, epidermoid cysts, cutaneous horns, hemangiomas, ichthyosis, leukoderma, pilar sheath tumor, dilated pore of Winer, trichoepithelioma, and other epidermal nevi.[23][24][25]
Enhancing Healthcare Team Outcomes
It is important to look for features of nevus comedonicus syndrome in any patient presenting with lesions suggestive of nevus comedonicus. Patients must be counseled regarding the possibility of intermittent flares. As of now there are no clear randomized control trials to clearly predict treatment success with any particularmodality, but patients must be madeaware of all available options so that an informed decision can be made.
Media
References
[1]
Tchernev G, Ananiev J, Semkova K, Dourmishev LA, Schönlebe J, Wollina U. Nevus comedonicus: an updated review. Dermatology and therapy. 2013 Jun:3(1):33-40. doi: 10.1007/s13555-013-0027-9. Epub 2013 May 25 [PubMed PMID: 23888253]
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[2]
Liu F, Yang Y, Zheng Y, Liang YH, Zeng K. Mutation and expression of ABCA12 in keratosis pilaris and nevus comedonicus. Molecular medicine reports. 2018 Sep:18(3):3153-3158. doi: 10.3892/mmr.2018.9342. Epub 2018 Jul 31 [PubMed PMID: 30066947]
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[3]
Levinsohn JL, Sugarman JL, Yale Center for Mendelian Genomics, McNiff JM, Antaya RJ, Choate KA. Somatic Mutations in NEK9 Cause Nevus Comedonicus. American journal of human genetics. 2016 May 5:98(5):1030-1037. doi: 10.1016/j.ajhg.2016.03.019. Epub [PubMed PMID: 27153399]
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B1)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[4]
Ferrari B, Taliercio V, Restrepo P, Luna P, Abad ME, Larralde M. Nevus comedonicus: a case series. Pediatric dermatology. 2015 Mar-Apr:32(2):216-9. doi: 10.1111/pde.12466. Epub 2014 Dec 29 [PubMed PMID: 25557057]
Level 2 (mid-level) evidence
", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B1)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[5]
Nabai H, Mehregan AH. Nevus comedonicus. A review of the literature and report of twelve cases. Acta dermato-venereologica. 1973:53(1):71-4 [PubMed PMID: 4120812]
Level 3 (low-level) evidence
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A2)"]').popover( { content: "A: Benefits outweigh the risks
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B2)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
2: Moderate level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(A3)"]').popover( { content: "A: Benefits outweigh the risks
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); $('a[refgrade*="(B3)"]').popover( { content: "B: Benefits and risk equivocal or uncertain
3: Low level of evidence", html: true, placement: "top", trigger:'hover' } ); });
[6]
Vidaurri-de la Cruz H, Tamayo-Sánchez L, Durán-McKinster C, de la Luz Orozco-Covarrubias M, Ruiz-Maldonado R. Epidermal nevus syndromes: clinical findings in 35 patients. Pediatric dermatology. 2004 Jul-Aug:21(4):432-9 [PubMed PMID: 15283784]
Level 2 (mid-level) evidence
[7]
Zanniello R, Pilloni L, Conti B, Faa G, Rongioletti F. Late-Onset Nevus Comedonicus With Follicular Epidermolytic Hyperkeratosis-Case Report and Review of the Literature. The American Journal of dermatopathology. 2019 Jun:41(6):453-455. doi: 10.1097/DAD.0000000000001317. Epub [PubMed PMID: 30461425]
Level 3 (low-level) evidence
[8]
Nevus comedonicus of the scalp., Kaliyadan F,Nambiar A,Al Ameer A,Amri M,, Skinmed, 2014 Jan-Feb [PubMed PMID: 24720088]
Level 3 (low-level) evidence
[9]
Ito T, Mitamura Y, Tsuji Y, Harada K, Urabe K. Bilateral nevus comedonicus syndrome. Yonago acta medica. 2013 Jun:56(2):59-61 [PubMed PMID: 24031154]
[10]
Abdel-Aal H, Abdel-Aziz AM. Nevus comedonicus. Report of three cases localized on glans penis. Acta dermato-venereologica. 1975:55(1):78-80 [PubMed PMID: 46679]
Level 3 (low-level) evidence
[11]
Cho SB, Oh SH, Lee JH, Bang D, Bang D. Ultrastructural features of nevus comedonicus. International journal of dermatology. 2012 May:51(5):626-8. doi: 10.1111/j.1365-4632.2010.04588.x. Epub 2011 Oct 5 [PubMed PMID: 21973328]
Level 3 (low-level) evidence
[12]
Kamińska-Winciorek G, Spiewak R. Dermoscopy on nevus comedonicus: a case report and review of the literature. Postepy dermatologii i alergologii. 2013 Aug:30(4):252-4. doi: 10.5114/pdia.2013.37036. Epub 2013 Aug 27 [PubMed PMID: 24278083]
Level 3 (low-level) evidence
[13]
Vora RV, Kota RS, Sheth NK. Dermoscopy of Nevus Comedonicus. Indian dermatology online journal. 2017 Sep-Oct:8(5):388-389. doi: 10.4103/idoj.IDOJ_430_16. Epub [PubMed PMID: 28979887]
[14]
Capusan TM, Chicharro P, Rodriguez-Jimenez P, Martinez-Mera C, Urquía A, Aragüés M, de Argila D. Successful treatment to a tretinoin/clindamycin gel in a late onset of nevus comedonicus. Dermatologic therapy. 2017 Jul:30(4):. doi: 10.1111/dth.12486. Epub 2017 Mar 14 [PubMed PMID: 28295844]
[15]
Zhu C, Sun A. Ultrapulse carbon dioxide laser treatment for bilateral facial nevus comedonicus: A case report. Dermatologic therapy. 2017 May:30(3):. doi: 10.1111/dth.12473. Epub 2017 Feb 15 [PubMed PMID: 28198069]
Level 3 (low-level) evidence
[16]
Qian G, Liu T, Zhou C, Zhang Y. Naevus comedonicus syndrome complicated by hidradenitis suppurativa-like lesions responding to acitretin treatment. Acta dermato-venereologica. 2015 Nov:95(8):992-3. doi: 10.2340/00015555-2089. Epub [PubMed PMID: 25758459]
Level 3 (low-level) evidence
[17]
Milton GP, DiGiovanna JJ, Peck GL. Treatment of nevus comedonicus with ammonium lactate lotion. Journal of the American Academy of Dermatology. 1989 Feb:20(2 Pt 2):324-8 [PubMed PMID: 2915076]
Level 3 (low-level) evidence
[18]
Polat M, Altunay Tuman B, Sahin A, Dogan U, Boran C. Bilateral nevus comedonicus of the eyelids associated with bladder cancer and successful treatment with topical tretinoin. Dermatologic therapy. 2016 Nov:29(6):479-481. doi: 10.1111/dth.12385. Epub 2016 Aug 9 [PubMed PMID: 27502087]
[19]
Kaliyadan F, Nampoothiri S, Sunitha V, Kuruvilla VE. Nevus comedonicus syndrome--nevus comedonicus associated with ipsilateral polysyndactyly and bilateral oligodontia. Pediatric dermatology. 2010 Jul-Aug:27(4):377-9. doi: 10.1111/j.1525-1470.2010.01170.x. Epub [PubMed PMID: 20653857]
Level 3 (low-level) evidence
[20]
Filosa G, Bugatti L, Ciattaglia G, Salaffi F, Carotti M. Naevus comedonicus as dermatologic hallmark of occult spinal dysraphism. Acta dermato-venereologica. 1997 May:77(3):243 [PubMed PMID: 9188888]
Level 3 (low-level) evidence
[21]
Sinha A, Natarajan S. Linear morhpea, nevus comedonicus, and lichen striatus in a 5-year-old girl. Pediatric dermatology. 2011 Jan-Feb:28(1):72-4. doi: 10.1111/j.1525-1470.2010.01250.x. Epub 2010 Sep 1 [PubMed PMID: 20825567]
Level 3 (low-level) evidence
[22]
Lee HJ, Chun EY, Kim YC, Lee MG. Nevus comedonicus with hidradenoma papilliferum and syringocystadenoma papilliferum in the female genital area. International journal of dermatology. 2002 Dec:41(12):933-6 [PubMed PMID: 12530358]
Level 3 (low-level) evidence
[23]
Ravaioli GM, Neri I, Zannetti G, Patrizi A. Congenital nevus comedonicus complicated by a hidradenitis suppurativa-like lesion: Report of a childhood case. Pediatric dermatology. 2018 Sep:35(5):e298-e299. doi: 10.1111/pde.13574. Epub 2018 Jun 27 [PubMed PMID: 29952017]
Level 3 (low-level) evidence
[24]
Woods KA, Larcher VF, Harper JI. Extensive naevus comedonicus in a child with Alagille syndrome. Clinical and experimental dermatology. 1994 Mar:19(2):163-4 [PubMed PMID: 8050150]
Level 3 (low-level) evidence
[25]
Martinez M, Levrero P, Bazzano C, Larre Borges A, De Anda G. Nevus comedonicus syndrome in a woman with Paget bone disease and breast cancer: a mere coincidence? European journal of dermatology : EJD. 2006 Nov-Dec:16(6):697-8 [PubMed PMID: 17229620]
Level 3 (low-level) evidence